eligibility_summary
Adults 18–70 with HER2+ measurable solid tumors refractory/relapsed after standard therapy, ECOG 0–1, life ≥3 mo, adequate organs, neg pregnancy test/contraception, consent. Exclude: pregnant/lactating, active HBV/HCV, HIV or syphilis, unresolved >G1 toxicity, prior allograft or anti‑HER2 CAR‑T, recent/planned major surgery, brain mets allowed if asymptomatic/stable off steroids ≥4 w, serious disease, severe drug allergy, recent live vaccine/other trial, other cancer ≤5 y (except some in situ/skin).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06658951 tests anti-HER2 CAR‑T cell therapy in HER2‑positive advanced solid tumors. Intervention: autologous CAR‑T cells (biological/cellular therapy) engineered to express a chimeric antigen receptor targeting HER2/ERBB2, leading to T‑cell activation, cytokine release, and cytotoxic killing of HER2‑expressing tumor cells. Preconditioning drugs: fludarabine (purine analog antimetabolite, lymphodepletion), cyclophosphamide (alkylating agent, lymphodepletion), and nab‑paclitaxel/ABRAXANE (taxane microtubule stabilizer, tumor debulking). Targets: HER2 on tumor cells (ERBB pathway), host lymphocytes for lymphodepletion to enhance CAR‑T expansion.